HopeStage
Back to all studies
RecruitingNCT06882785

KarXT for acute psychosis in Japanese adults with schizophrenia

About this titleRead the official source — NCT06882785

This study evaluates the safety and effectiveness of KarXT for people with schizophrenia.

Medication studyAges 18–65Japan
The study in practice

Understand this study

What is this study about?

This study evaluates the safety and effectiveness of KarXT for people with schizophrenia.

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
Kōnan and 55 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: June 10, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
250
Sponsor
Bristol-Myers Squibb
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Japan
Age range
From 18 Years to 65 Years
Official registry ID
NCT06882785
Official title
Show the full official title

A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallelgroup, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia

Recruitment & locations

Currently recruiting

Kōnan · Nagoya · Toyoake

48 more locations
  • Ichikawa
  • Iizuka
  • Kitakyushu
  • Omuta
  • Aizu-Wakamatsu
  • Toki
  • Kure
  • Sapporo
  • Hadano-shi
  • Hiratsuka
  • Sagamihara
  • Yokohama
  • Kumamoto
  • Yatsushiro
  • Maizuru
  • Miyakonojō
  • Komoro
  • Matsumoto
  • Ginowan
  • Hirakata
  • Moriguchi
  • Neyagawa
  • Takatsuki
  • Karatsu-shi
  • Tosu
  • Kumagaya
  • Shimotsuga
  • Shimotsuke
  • Utsunomiya
  • Hachiōji
  • Kodaira
  • Machida
  • Ōta-ku
  • Setagaya City
  • tabashi City
  • Ube
  • Chiba
  • Fukuoka
  • Kyoto
  • Miyazaki
  • Okayama
  • Okinawa
  • Osaka
  • Saitama
  • Tokushima
  • Tottori
  • Wakayama
  • Yamagata

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the safety and effectiveness of KarXT for people with schizophrenia.

Who is behind this study?

The study sponsor is Bristol-Myers Squibb, a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including KarXT.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies